44 results on '"Atsuta, Yoshiko"'
Search Results
2. Age and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia
- Author
-
Yanada, Masamitsu, Yamasaki, Satoshi, Konuma, Takaaki, Mizuno, Shohei, Uchida, Naoyuki, Onai, Daishi, Fukuda, Takahiro, Tanaka, Masatsugu, Ozawa, Yukiyasu, Eto, Tetsuya, Ikegame, Kazuhiro, Sawa, Masashi, Katayama, Yuta, Kawakita, Toshiro, Onizuka, Makoto, Kanda, Yoshinobu, Ichinohe, Tatsuo, Atsuta, Yoshiko, and Yano, Shingo
- Published
- 2023
- Full Text
- View/download PDF
3. Donor lymphocyte infusion after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia
- Author
-
Harada, Kaito, Mizuno, Shohei, Yano, Shingo, Takami, Akiyoshi, Ishii, Hiroto, Ikegame, Kazuhiro, Najima, Yuho, Kako, Shinichi, Ashida, Takashi, Shiratori, Souichi, Ota, Shuichi, Onizuka, Makoto, Fukushima, Kentaro, Fukuda, Takahiro, Ichinohe, Tatsuo, Atsuta, Yoshiko, and Yanada, Masamitsu
- Published
- 2022
- Full Text
- View/download PDF
4. The differential effect of disease status at allogeneic hematopoietic cell transplantation on outcomes in acute myeloid and lymphoblastic leukemia
- Author
-
Yanada, Masamitsu, Konuma, Takaaki, Yamasaki, Satoshi, Mizuno, Shohei, Hirabayashi, Shigeki, Nishiwaki, Satoshi, Uchida, Naoyuki, Doki, Noriko, Tanaka, Masatsugu, Ozawa, Yukiyasu, Sawa, Masashi, Eto, Tetsuya, Kawakita, Toshiro, Ota, Shuichi, Fukuda, Takahiro, Onizuka, Makoto, Kimura, Takafumi, Atsuta, Yoshiko, Kako, Shinichi, and Yano, Shingo
- Published
- 2021
- Full Text
- View/download PDF
5. Single cord blood transplantation for acute myeloid leukemia patients aged 60 years or older: a retrospective study in Japan
- Author
-
Isobe, Masamichi, Konuma, Takaaki, Masuko, Masayoshi, Uchida, Naoyuki, Miyakoshi, Shigesaburo, Sugio, Yasuhiro, Yoshida, Shuro, Tanaka, Masatsugu, Matsuhashi, Yoshiko, Hattori, Norimichi, Onizuka, Makoto, Aotsuka, Nobuyuki, Kouzai, Yasushi, Wake, Atsushi, Kimura, Takafumi, Ichinohe, Tatsuo, Atsuta, Yoshiko, and Yanada, Masamitsu
- Published
- 2021
- Full Text
- View/download PDF
6. Effect of allogeneic HCT from unrelated donors in AML patients with intermediate- or poor-risk cytogenetics: a retrospective study from the Japanese Society for HCT
- Author
-
Yamasaki, Satoshi, Mori, Jinichi, Kanda, Junya, Imahashi, Nobuhiko, Uchida, Naoyuki, Doki, Noriko, Tanaka, Masatsugu, Katayama, Yuta, Eto, Tetsuya, Ozawa, Yukiyasu, Takada, Satoru, Onizuka, Makoto, Hino, Masayuki, Kanda, Yoshinobu, Fukuda, Takahiro, Atsuta, Yoshiko, and Yanada, Masamitsu
- Published
- 2020
- Full Text
- View/download PDF
7. Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia conducted in Japan during the past quarter century
- Author
-
Yanada, Masamitsu, Takami, Akiyoshi, Yamasaki, Satoshi, Arai, Yasuyuki, Konuma, Takaaki, Uchida, Naoyuki, Najima, Yuho, Fukuda, Takahiro, Tanaka, Masatsugu, Ozawa, Yukiyasu, Ikegame, Kazuhiro, Takanashi, Minoko, Ichinohe, Tatsuo, Okamoto, Shinichiro, Atsuta, Yoshiko, and Yano, Shingo
- Published
- 2020
- Full Text
- View/download PDF
8. Autologous hematopoietic cell transplantation for acute myeloid leukemia in adults: 25 years of experience in Japan
- Author
-
Yanada, Masamitsu, Takami, Akiyoshi, Mizuno, Shohei, Mori, Jinichi, Chou, Takaaki, Usuki, Kensuke, Uchiyama, Hitoji, Amano, Itsuto, Fujii, Shiro, Miyamoto, Toshihiro, Saito, Takeshi, Kamimura, Tomohiko, Ichinohe, Tatsuo, Fukuda, Takahiro, Okamoto, Shinichiro, Atsuta, Yoshiko, and Yano, Shingo
- Published
- 2020
- Full Text
- View/download PDF
9. Allogeneic hematopoietic cell transplantation for patients with a history of multiple relapses of acute myeloid leukemia
- Author
-
Yanada, Masamitsu, Mori, Jinichi, Aoki, Jun, Masuko, Masayoshi, Harada, Kaito, Uchida, Naoyuki, Doki, Noriko, Fukuda, Takahiro, Sakura, Toru, Kanamori, Heiwa, Sawa, Masashi, Kondo, Tadakazu, Katayama, Yuta, Kanda, Junya, Ichinohe, Tatsuo, Atsuta, Yoshiko, and Yano, Shingo
- Published
- 2019
- Full Text
- View/download PDF
10. Allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia with 11q23 abnormality: a retrospective study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT)
- Author
-
Konuma, Takaaki, Mizuno, Shohei, Kondo, Tadakazu, Yamaguchi, Hiroki, Fukuda, Takahiro, Uchida, Naoyuki, Najima, Yuho, Kanamori, Heiwa, Ota, Shuichi, Nakamae, Hirohisa, Nakamae, Mika, Mizuno, Ishikazu, Sugita, Junichi, Onishi, Yasushi, Yokota, Akira, Takahashi, Satoshi, Kanda, Yoshinobu, Ichinohe, Tatsuo, Atsuta, Yoshiko, Yano, Shingo, and Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation
- Published
- 2018
- Full Text
- View/download PDF
11. Poor outcome of allogeneic transplantation for therapy-related acute myeloid leukemia induced by prior chemoradiotherapy.
- Author
-
Araie, Hiroaki, Arai, Yasuyuki, Kida, Michiko, Aoki, Jun, Uchida, Naoyuki, Doki, Noriko, Fukuda, Takahiro, Tanaka, Masatsugu, Ozawa, Yukiyasu, Sawa, Masashi, Katayama, Yuta, Matsuo, Yayoi, Onizuka, Makoto, Kanda, Yoshinobu, Kawakita, Toshiro, Kanda, Junya, Atsuta, Yoshiko, and Yanada, Masamitsu
- Subjects
ACUTE myeloid leukemia ,STEM cell transplantation ,HEMATOPOIETIC stem cell transplantation ,TREATMENT effectiveness ,PROPENSITY score matching ,CHEMORADIOTHERAPY ,PROGNOSIS - Abstract
Therapy-related acute myeloid leukemia (t-AML) is a therapeutic challenge as a late complication of chemotherapy (CHT) and/or radiotherapy (RT) for primary malignancy. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) presents itself as a curative approach. To establish the optimal allo-HSCT strategy for t-AML, we evaluated the relationship between characteristics of primary malignancy and allo-HSCT outcomes. Patients with t-AML or de novo acute myeloid leukemia (AML) who underwent first allo-HSCT in Japan from 2011 to 2018 were identified using a nationwide database. The detailed background of t-AML was obtained by additional questionnaires. Multivariate analysis and propensity score matching (PSM) analysis were performed to detect the prognostic factors associated with t-AML and compare outcomes with de novo AML. We analyzed 285 t-AML and 6761 de novo AML patients. In patients with t-AML, receiving both CHT and RT for primary malignancy was an independent poor-risk factor for relapse and overall survival (OS) (hazard ratio (HR) 1.62; p = 0.029 and HR 1.65; p = 0.009, reference: CHT alone group), whereas other primary malignancy-related factors had no effect on the outcome. Compared to the CHT alone group, complex karyotypes were significantly increased in the CHT + RT group (86.1% vs. 57.5%, p = 0.007). In the PSM cohort, t-AML patients with prior CHT and RT had significantly worse 3-year OS than those with de novo AML (25.2% and 42.7%; p = 0.009). Our results suggest that prior CHT and RT for primary malignancy may be associated with increased relapse and worse OS of allo-HSCT in t-AML. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
12. Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia harboring trisomy 8
- Author
-
Konuma, Takaaki, Kondo, Tadakazu, Yamashita, Takuya, Uchida, Naoyuki, Fukuda, Takahiro, Ozawa, Yukiyasu, Ohashi, Kazuteru, Ogawa, Hiroyasu, Kato, Chiaki, Takahashi, Satoshi, Kanamori, Heiwa, Eto, Tetsuya, Nakaseko, Chiaki, Kohno, Akio, Ichinohe, Tatsuo, Atsuta, Yoshiko, Takami, Akiyoshi, Yano, Shingo, and Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT)
- Published
- 2017
- Full Text
- View/download PDF
13. Role of reduced-intensity conditioning allogeneic hematopoietic cell transplantation in older patients with de novo acute myeloid leukemia
- Author
-
Yamasaki, Satoshi, Hirakawa, Akihiro, Aoki, Jun, Uchida, Naoyuki, Fukuda, Takahiro, Ogawa, Hiroyasu, Ohashi, Kazuteru, Kondo, Tadakazu, Eto, Tetsuya, Kanamori, Heiwa, Okumura, Hirokazu, Iwato, Koji, Ichinohe, Tatsuo, Kanda, Junya, Onizuka, Makoto, Kuwatsuka, Yachiyo, Yanada, Masamitsu, Atsuta, Yoshiko, Takami, Akiyoshi, and Yano, Shingo
- Published
- 2017
- Full Text
- View/download PDF
14. Prognostic impact of complex and/or monosomal karyotypes in post‐transplant poor cytogenetic acute myeloid leukaemia: A quantitative approach.
- Author
-
Jo, Tomoyasu, Arai, Yasuyuki, Oshima, Shinichiro, Kondo, Tadakazu, Harada, Kaito, Uchida, Naoyuki, Doki, Noriko, Fukuda, Takahiro, Tanaka, Masatsugu, Ozawa, Yukiyasu, Kuriyama, Takuro, Ikegame, Kazuhiro, Katayama, Yuta, Ota, Shuichi, Ara, Takahide, Kawakita, Toshiro, Onizuka, Makoto, Ichinohe, Tatsuo, Atsuta, Yoshiko, and Yanada, Masamitsu
- Subjects
ACUTE myeloid leukemia ,STEM cell transplantation ,KARYOTYPES ,STEM cell factor ,DISEASE risk factors ,HEMATOPOIETIC stem cell transplantation - Abstract
Summary: To evaluate the prognostic impact of complex karyotype (CK) and/or monosomal karyotype (MK) in combination with various clinical factors on allogeneic stem cell transplantation (HSCT) outcomes of patients with acute myeloid leukaemia (AML), we analysed the registry database of adult AML patients who underwent allogeneic HSCT between 2000 and 2019 in Japan. Among 16 094 patients, those with poor cytogenetic risk (N = 3345) showed poor overall survival (OS) after HSCT (25.3% at 5 years). Multivariate analyses revealed that CK and/or MK (hazard ratio [HR], 1.31 for CK without MK; 1.27 for MK without CK; and 1.73 for both), age at HSCT ≥50 years (HR, 1.58), male sex (HR, 1.40), performance status ≥2 (HR, 1.89), HCT‐CI score ≥3 (HR, 1.23), non‐remission status at HSCT (HR, 2.49), and time from diagnosis to HSCT ≥3 months (HR, 1.24) independently reduced post‐HSCT OS among patients with poor cytogenetic risk AML. A risk scoring system based on the multivariate analysis successfully stratified patients into five distinct groups for OS. This study confirms the negative effects of CK and MK on post‐HSCT outcomes, and offers a powerful risk scoring system for predicting prognoses after HSCT among AML patients with unfavourable cytogenetics. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Allogeneic transplantation of bone marrow versus peripheral blood stem cells from HLA-identical relatives in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukemia: a propensity score analysis of a nationwide database.
- Author
-
Itonaga, Hidehiro, Miyazaki, Yasushi, Aoki, Kazunari, Shingai, Naoki, Ozawa, Yukiyasu, Fukuda, Takahiro, Kataoka, Keisuke, Kawakita, Toshiro, Ueda, Yasunori, Ara, Takahide, Tanaka, Masatsugu, Katayama, Yuta, Sawa, Masashi, Eto, Tetsuya, Kanda, Junya, Atsuta, Yoshiko, and Ishiyama, Ken
- Subjects
MYELODYSPLASTIC syndromes ,BONE marrow transplantation ,ACUTE myeloid leukemia ,BLOOD cells ,STEM cells ,HEPATIC veno-occlusive disease - Abstract
Bone marrow (BM) and granulocyte colony-stimulating factor-mobilized peripheral blood stem cells (PBSC) are used as grafts from HLA-identical-related donors for adults with myelodysplastic syndrome (MDS). To assess the impact of graft sources on post-transplant outcomes in MDS patients, we conducted a retrospective analysis of a nationwide database. A total of 247 and 280 patients underwent transplantation with BM and PBSC, respectively. The inverse probability of treatment weighting (IPTW) methods revealed that overall survival (OS) was comparable between BM and PBSC (P =.129), but PBSC transplantation was associated with worse graft-versus-host disease (GVHD)-free/relapse-free survival (GRFS) (hazard rate [HR], 1.24; 95% confidence intervals [CIs], 1.00–1.53; P = 0.049) and chronic GVHD-free and relapse-free survival (CRFS) (HR, 1.29; 95% CIs, 1.13–1.73; P = 0.002) than BM transplantation. In the propensity score matched cohort (BM, n = 216; PBSC, n = 216), no significant differences were observed in OS and relapse; 3-year OS rates were 64.7% and 60.0% (P = 0.107), while 3-year relapse rates were 27.1% and 23.5% (P = 0.255) in BM and PBSC, respectively. Three-year GRFS rates (36.6% vs. 29.2%; P = 0.006), CRFS rate (37.7% vs. 32.5%; P = 0.003), and non-relapse mortality rates (13.9% vs. 21.1%; P = 0.020) were better in BM than in PBSC. The present study showed that BM transplantation provides a comparable survival benefit with PBSC transplantation and did not identify an enhanced graft-versus-MDS effect to reduce the incidence of relapse in PBSC transplantation. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. Outcome of therapy‐related myelodysplastic syndrome and oligoblastic acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: A propensity score matched analysis.
- Author
-
Itonaga, Hidehiro, Kida, Michiko, Hamamura, Atsushi, Uchida, Naoyuki, Ozawa, Yukiyasu, Fukuda, Takahiro, Ueda, Yasunori, Kataoka, Keisuke, Katayama, Yuta, Ota, Shuichi, Matsuoka, Ken‐ichi, Kondo, Tadakazu, Eto, Tetsuya, Kanda, Junya, Ichinohe, Tatsuo, Atsuta, Yoshiko, Miyazaki, Yasushi, and Ishiyama, Ken
- Subjects
HEMATOPOIETIC stem cell transplantation ,STEM cell transplantation ,ACUTE myeloid leukemia ,MYELODYSPLASTIC syndromes ,PROPENSITY score matching ,AGE groups ,HEPATIC veno-occlusive disease - Abstract
Therapy‐related myelodysplastic syndromes (t‐MDS) are generally progressive and associated with poorer outcomes than de novo MDS (d‐MDS). To evaluate the outcome of allogeneic hematopoietic stem cell transplantation (allo‐HSCT) for t‐MDS, we conducted a propensity score matched‐pair analysis of patients with t‐MDS and d‐MDS using a nationwide database. A total of 178 patients with t‐MDS underwent allo‐HSCT between 2001 and 2018, and 178 out of 3123 patients with d‐MDS were selected. The probability of 3‐year overall survival rate was 40.0% and 50.0% in the t‐MDS and d‐MDS groups, respectively (p = 0.032). The 3‐year transplant‐related mortality was 30.9% and 19.0% in the t‐MDS and d‐MDS groups, respectively (p = 0.005). The 3‐year cumulative incidence of relapse was 32.8% and 33.0% in the t‐MDS and d‐MDS groups, respectively (p = 0.983). A multivariate analysis identified four adverse factors for overall survival in the t‐MDS group: age ≥ 55 years (hazard ratio [HR], 2.09; 95% CI, 1.11–3.94; p = 0.023), the poor cytogenetic risk group (HR, 2.19; 95% CI, 1.40–4.19; p = 0.019), performance status at allo‐HSCT 2–4 (HR, 2.14; 95% CI, 1.19–3.86; p = 0.011), and a shorter interval from diagnosis to transplantation (<8 months; HR, 1.61; 95% CI, 1.00–2.57; p = 0.048). The most frequent cause of transplant‐related death was the infectious complications (21.6%) in t‐MDS group and organ failure (12.5%) in d‐MDS group. In conclusion, allo‐HSCT potentially provides long‐term remission in patients with t‐MDS; however, further efforts to reduce transplant‐related death are needed. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
17. Improved trends in survival and engraftment after single cord blood transplantation for adult acute myeloid leukemia.
- Author
-
Konuma, Takaaki, Mizuno, Shohei, Kondo, Tadakazu, Arai, Yasuyuki, Uchida, Naoyuki, Takahashi, Satoshi, Tanaka, Masatsugu, Kuriyama, Takuro, Miyakoshi, Shigesaburo, Onizuka, Makoto, Ota, Shuichi, Sugio, Yasuhiro, Kouzai, Yasushi, Kawakita, Toshiro, Kobayashi, Hikaru, Ozawa, Yukiyasu, Kimura, Takafumi, Ichinohe, Tatsuo, Atsuta, Yoshiko, and Yanada, Masamitsu
- Subjects
CORD blood transplantation ,ACUTE myeloid leukemia ,HEMATOPOIETIC stem cell transplantation ,OVERALL survival ,ADULTS - Abstract
Unrelated cord blood transplantation (CBT) is an alternative curative option for adult patients with acute myeloid leukemia (AML) who need allogeneic hematopoietic cell transplantation (HCT) but lack an HLA-matched related or unrelated donor. However, large-scale data are lacking on CBT outcomes for unselected adult AML. To investigate the trends of survival and engraftment after CBT over the past 22 years, we retrospectively evaluated the data of patients with AML in Japan according to the time period of CBT (1998–2007 vs 2008–2013 vs 2014–2019). A total of 5504 patients who received single-unit CBT as first allogeneic HCT for AML were included. Overall survival (OS) at 2 years significantly improved over time. The improved OS among patients in ≥ complete remission (CR)3 and active disease at CBT was mainly due to a reduction of relapse-related mortality, whereas among patients in first or second CR at CBT, this was due mainly to a reduction of non-relapse mortality. The trends of neutrophil engraftment also improved over time. This experience demonstrated that the survival and engraftment rate after CBT for this group has improved over the past 22 years. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
18. Syngeneic hematopoietic stem cell transplantation for acute myeloid leukemia: a propensity score-matched analysis.
- Author
-
Kurosawa, Shuhei, Mizuno, Shohei, Arai, Yasuyuki, Masuko, Masayoshi, Kanda, Junya, Kohno, Kentaro, Onai, Daishi, Fukuda, Takahiro, Ozawa, Yukiyasu, Katayama, Yuta, Tanaka, Masatsugu, Ikegame, Kazuhiro, Uchida, Naoyuki, Eto, Tetsuya, Ota, Shuichi, Tanaka, Junji, Ichinohe, Tatsuo, Atsuta, Yoshiko, and Yanada, Masamitsu
- Subjects
HEMATOPOIETIC stem cell transplantation ,ACUTE myeloid leukemia ,HLA histocompatibility antigens ,OVERALL survival ,PROGNOSIS - Abstract
The present study evaluated outcomes and prognostic factors in adult patients with acute myeloid leukemia (AML) after syngeneic hematopoietic stem cell transplantation (HSCT). Among patients in first complete remission (CR1), outcomes of syngeneic HSCT (Syn) were compared with those of autologous HSCT (Auto), allogeneic HSCT from human leukocyte antigen (HLA)-matched sibling donor (MSD), or allogeneic HSCT from HLA-matched unrelated donor (MUD). Among 11,866 patients receiving first HSCT, 26 in the Syn group were analyzed. The 5-year overall survival (OS) rate, the cumulative incidence of relapse, and the cumulative incidence of non-relapse mortality (NRM) were 47.8%, 59.6%, and 4.6%, respectively. The OS was significantly better in patients in CR1 (n = 13) than in patients in non-CR1 (P = 0.012). Furthermore, 39 patients in CR1 each were assigned to the Auto, MSD, and MUD groups using propensity score matching. The 5-year OS in the Syn (68.4%) was not significantly different from those in the Auto (55.9%, P = 0.265), MSD (62.4%, P = 0.419), or MUD (63.7%, P = 0.409) groups. A higher relapse in the Syn than in the MSD and MUD groups was offset by lower NRM. In summary, syngeneic HSCT might be an alternative option for AML patients in CR1. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
19. Personalized prediction of overall survival in patients with AML in non‐complete remission undergoing allo‐HCT.
- Author
-
Hirabayashi, Shigeki, Uozumi, Ryuji, Kondo, Tadakazu, Arai, Yasuyuki, Kawata, Takahito, Uchida, Naoyuki, Marumo, Atsushi, Ikegame, Kazuhiro, Fukuda, Takahiro, Eto, Tetsuya, Tanaka, Masatsugu, Wake, Atsushi, Kanda, Junya, Kimura, Takafumi, Tabuchi, Ken, Ichinohe, Tatsuo, Atsuta, Yoshiko, Yanada, Masamitsu, and Yano, Shingo
- Subjects
HEMATOPOIETIC stem cell transplantation ,STEM cell transplantation ,OVERALL survival ,CORD blood transplantation ,PROGNOSIS ,BONE marrow transplantation ,TOTAL body irradiation - Abstract
Allogenic hematopoietic stem cell transplantation (allo‐HCT) is the standard treatment for acute myeloid leukemia (AML) in non‐complete remission (non‐CR); however, the prognosis is inconsistent. This study aimed to develop and validate nomograms and a web application to predict the overall survival (OS) of patients with non‐CR AML undergoing allo‐HCT (cord blood transplantation [CBT], bone marrow transplantation [BMT], and peripheral blood stem cell transplantation [PBSCT]). Data from 3052 patients were analyzed to construct and validate the prognostic models. The common significant prognostic factors among patients undergoing allo‐HCT were age, performance status, percentage of peripheral blasts, cytogenetic risk, chemotherapy response, and number of transplantations. The conditioning regimen was a significant prognostic factor only in patients undergoing CBT. Compared with cyclophosphamide/total body irradiation, a conditioning regimen of ≥3 drugs, including fludarabine, with CBT exhibited the lowest hazard ratio for mortality (0.384; 95% CI, 0.266–0.554; p < 0.0001). A conditioning regimen of ≥3 drugs with CBT also showed the best leukemia‐free survival among all conditioning regimens. Based on the results of the multivariable analysis, we developed prognostic models showing adequate calibration and discrimination (the c‐indices for CBT, BMT, and PBSCT were 0.648, 0.600, and 0.658, respectively). Our prognostic models can help in assessing individual risks and designing future clinical studies. Furthermore, our study indicates the effectiveness of multi‐drug conditioning regimens in patients undergoing CBT. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
20. Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3‐internal tandem duplication AML: The JALSG AML209‐FLT3‐SCT study.
- Author
-
Kawashima, Naomi, Ishikawa, Yuichi, Atsuta, Yoshiko, Sawa, Masashi, Ozawa, Yukiyasu, Hayashi, Masaki, Kohno, Akio, Tomita, Akihiro, Maeda, Tomoya, Sakaida, Emiko, Usuki, Kensuke, Hagihara, Maki, Kanamori, Heiwa, Matsuoka, Hiroshi, Kobayashi, Miki, Asou, Norio, Ohtake, Shigeki, Matsumura, Itaru, Miyazaki, Yasushi, and Naoe, Tomoki
- Abstract
In this phase II multicenter study (JALSG AML209‐FLT3‐SCT), we aimed to prospectively elucidate the role of allogeneic hematopoietic stem cell transplantation (allo‐HSCT) at first complete remission (CR1) for FLT3‐internal tandem duplication (ITD)‐positive AML. Newly diagnosed de novo AML patients with FLT3‐ITD were enrolled at the achievement of CR1 and received allo‐HSCT as soon as possible after the first consolidation therapy. Mutations of 57 genes in AML cells at diagnosis were also analyzed. Among 48 eligible patients with a median age of 38.5 (17‐49) years, 36 (75%) received allo‐HSCT at a median of 108 days after CR1. The median follow‐up was 1726 days. The primary end‐point, 3‐year disease‐free survival (DFS) based on an intent to treat analysis, was 43.8% (95% confidence interval [CI], 30%‐57%), suggesting the efficacy of this treatment because the lower limit of the 95% CI exceeded the threshold response rate of 20%. The 3‐year overall survival, post‐transplant DFS, and non‐relapse mortality rates were 54.2% (95% CI, 39%‐67%), 58.3% (95% CI, 41%‐72%), and 25.0% (95% CI, 12%‐40%), respectively. The median ITD allelic ratio (AR) was 0.344 (0.006‐4.099). Neither FLT3‐ITD AR nor cooccurring genetic alterations was associated with a poor DFS. This prospective study indicated the efficacy and safety of allo‐HSCT for FLT3‐ITD AML patients in CR1. This study was registered at: www.umin.ac.jp/ctr/ as #UMIN000003433. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
21. Prognostic impact of melphalan dose and total body irradiation use in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation with reduced-intensity conditioning.
- Author
-
Harada, Kaito, Machida, Shinichiro, Onizuka, Makoto, Ichinohe, Tatsuo, Atsuta, Yoshiko, Yano, Shingo, Yanada, Masamitsu, Kanamori, Heiwa, Ozawa, Yukiyasu, Kobayashi, Hikaru, Sawa, Masashi, Katayama, Yuta, Ohashi, Kazuteru, and Kanda, Junya
- Subjects
TOTAL body irradiation ,ACUTE myeloid leukemia ,STEM cell transplantation ,HEMATOPOIETIC stem cell transplantation - Abstract
To evaluate the prognostic impact of melphalan dose and total body irradiation (TBI) use in acute myeloid leukemia patients undergoing reduced-intensity allogeneic transplantation, we retrospectively compared outcomes of patients receiving a higher-dose (120–140 mg/m
2 , n = 379) or lower-dose melphalan (80–110 mg/m2 , n = 128) with or without TBI of ≤4 Gy. At 3 years, overall survival was 48.9% in the higher-dose group versus 40.3% in the lower-dose group (p =.013). This survival benefit was attributed to lower tumor-related mortality (23.9% vs. 31.7%; p =.049). Non-relapse mortality did not differ (24.8% vs. 23.5%, p =.59). The beneficial effect of a higher-dose melphalan was more evident when combined with TBI in younger patients, those not in complete remission, and those with good performance status. Our findings support the use of a higher-dose melphalan in combination with TBI for reduced-intensity conditioning in physically fit patients. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
22. Allogeneic haematopoietic cell transplantation for adult acute myeloid leukaemia in second remission: a retrospective study of the Adult Acute Myeloid Leukaemia Working Group of the Japan Society for Haematopoietic Cell Transplantation (JSHCT).
- Author
-
Konuma, Takaaki, Yanada, Masamitsu, Yamasaki, Satoshi, Kuwatsuka, Yachiyo, Fukuda, Takahiro, Kobayashi, Takeshi, Ozawa, Yukiyasu, Uchida, Naoyuki, Ota, Shuichi, Hoshino, Takumi, Takahashi, Satoshi, Kanda, Yoshinobu, Ueda, Yasunori, Takanashi, Minoko, Kanda, Junya, Ichinohe, Tatsuo, Atsuta, Yoshiko, and Yano, Shingo
- Subjects
HEMATOPOIETIC stem cell transplantation ,ACUTE myeloid leukemia ,CYTOGENETICS ,MYELOID leukemia ,CYTOLOGY - Abstract
Summary: To evaluate the outcomes and prognostic factors following allogeneic haematopoietic cell transplantation (HCT) for adult acute myeloid leukaemia (AML) in second complete remission (CR2), we retrospectively analysed the Japanese registration data of 1080 adult AML patients in CR2 who had received allogeneic HCT. The probability of overall survival and the cumulative incidence of relapse at 3 years was 66% and 19%, respectively. In multivariate analysis, older age, poor cytogenetics and shorter duration of first complete remission were significantly associated with a higher overall mortality. Our data demonstrated the significant efficacy of allogeneic HCT for adult AML in CR2. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
23. Effect of cytogenetic risk status on outcomes for patients with acute myeloid leukemia undergoing various types of allogeneic hematopoietic cell transplantation: an analysis of 7812 patients.
- Author
-
Yanada, Masamitsu, Mori, Jinichi, Aoki, Jun, Harada, Kaito, Mizuno, Shohei, Uchida, Naoyuki, Kurosawa, Saiko, Toya, Takashi, Kanamori, Heiwa, Ozawa, Yukiyasu, Ogawa, Hiroyasu, Henzan, Hideho, Iwato, Koji, Sakura, Toru, Ota, Shuichi, Fukuda, Takahiro, Ichinohe, Tatsuo, Atsuta, Yoshiko, and Yano, Shingo
- Subjects
ACUTE myeloid leukemia treatment ,GRAFT versus host disease ,T-cell lymphoma ,HEMATOPOIETIC system ,HEMATOPOIESIS ,GRAFT versus host reaction ,IMMUNOLOGIC diseases - Abstract
This study aimed at determining how cytogenetic risk status affects outcomes for patients with acute myeloid leukemia (AML) after undergoing various types of allogeneic hematopoietic cell transplantation (HCT). Of 7812 patients eligible for analysis, cytogenetic risk was classified as favorable for 1088, intermediate for 5025, and poor for 1699. Overall, multivariate analysis showed significant intergroup differences in terms of relapse and survival, with the difference between poor- and intermediate-risk groups being greater than that between favorable- and intermediate-risk groups. Non-relapse mortality was identical for the three groups. Significant effects of cytogenetic risk status on survival were documented irrespective of donor type (related, unrelated, and umbilical cord blood), disease status at the time of transplantation (first or second complete remission, and more advanced disease status), and conditioning intensity (myeloablative and reduced-intensity). Our findings demonstrate robust and constant effects of cytogenetic risk status on survival after allogeneic HCT for patients with AML. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
24. Unrelated bone marrow transplantation or immediate umbilical cord blood transplantation for patients with acute myeloid leukemia in first complete remission.
- Author
-
Yanada, Masamitsu, Kanda, Junya, Ohtake, Shigeki, Fukuda, Takahiro, Sakamaki, Hisashi, Miyamura, Koichi, Miyawaki, Shuichi, Uchida, Naoyuki, Maeda, Tomoya, Nagamura‐Inoue, Tokiko, Asou, Norio, Morishima, Yasuo, Atsuta, Yoshiko, Miyazaki, Yasushi, Kimura, Fumihiko, Kobayashi, Yukio, Takami, Akiyoshi, Naoe, Tomoki, and Kanda, Yoshinobu
- Subjects
BONE marrow transplantation ,UMBILICAL cord ,ACUTE myeloid leukemia ,CYTOGENETICS ,CANCER chemotherapy - Abstract
Background While unrelated bone marrow transplantation ( UBMT) has been widely used as alternative donor transplantation, the use of umbilical cord blood transplantation ( UCBT) is increasing recently. Methods We conducted a decision analysis to address which transplantation procedure should be prioritized for younger patients with acute myeloid leukemia ( AML) harboring high- or intermediate-risk cytogenetics in first complete remission ( CR1), when they lack a matched related donor but have immediate access to a suitable umbilical cord blood unit. Main sources for our analysis comprised the data from three phase III trials for a chemotherapy cohort ( n = 907) and the registry data for a transplantation cohort ( n = 752). Results The baseline analysis showed that when the 8/8 match was considered for UBMT, the expected 5-year survival rate was higher for UBMT than for UCBT (58.1% vs. 51.8%). This ranking did not change even when the 7/8 match was considered for UBMT. Sensitivity analysis showed consistent superiority of UBMT over UCBT when the time elapsed between CR1 and UBMT was varied within a plausible range of 3-9 months. Conclusions These results suggest that 8/8 or 7/8 UBMT is a better transplantation option than UCBT even after allowing time required for donor coordination. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
25. Impact on relapse of corticosteroid therapy after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.
- Author
-
Imahashi, Nobuhiko, Inamoto, Yoshihiro, Seto, Aika, Watanabe, Keisuke, Nishiwaki, Satoshi, Yanagisawa, Mayumi, Shinba, Makoto, Yasuda, Takahiko, Kuwatsuka, Yachiyo, Atsuta, Yoshiko, Kodera, Yoshihisa, and Miyamura, Koichi
- Subjects
ACUTE myeloid leukemia ,DISEASE relapse ,CORTICOSTEROIDS ,HEMATOPOIETIC stem cells ,STEM cell transplantation ,GRAFT versus host disease ,MULTIVARIATE analysis ,DRUG delivery systems ,CONFIDENCE intervals - Abstract
Imahashi N, Inamoto Y, Seto A, Watanabe K, Nishiwaki S, Yanagisawa M, Shinba M, Yasuda T, Kuwatsuka Y, Atsuta Y, Kodera Y, Miyamura K. Impact on relapse of corticosteroid therapy after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. Clin Transplant 2010: 24: 772-777. © 2009 John Wiley & Sons A/S. Corticosteroids are often used following allogeneic hematopoietic stem cell transplantation (HSCT) to control complications such as graft-versus-host disease (GVHD). However, there is some concern that corticosteroids may suppress the graft-versus-leukemia effect and increase leukemia relapse. To evaluate the effect of corticosteroids on relapse, we analyzed 112 adult patients who received their first allogeneic HSCT for acute myeloid leukemia at our institution between 1997 and 2007. Fifty-seven patients (50.9%) received corticosteroid therapy. Patients who had corticosteroid therapy included higher proportion of patients who developed GVHD. In multivariate analysis, with corticosteroid administration entered as a time-dependent covariate, corticosteroid administration was not a risk factor for relapse (p = 1.00, hazard ratio [HR] 1.00, 95% confidence interval [CI] 0.53-1.88), but it was associated with higher non-relapse mortality (NRM) (p < 0.001, HR 55.5, 95% CI 7.42-416) and lower overall survival (p < 0.001, HR 2.68, 95% CI 1.56-4.61). The higher NRM associated with corticosteroid administration was mainly due to the increased deaths caused by the complications themselves, which required corticosteroid therapy. The findings of this study indicate the importance of controlling complications after allogeneic HSCT. The strategy of refraining from indispensable corticosteroid therapy because of the excessive concerns about relapse should be avoided. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
26. Prognostic factors in haploidentical transplantation with post-transplant cyclophosphamide for acute myeloid leukemia.
- Author
-
Shibata, Sho, Arai, Yasuyuki, Kondo, Tadakazu, Mizuno, Shohei, Yamasaki, Satoshi, Akasaka, Takashi, Doki, Noriko, Ota, Shuichi, Maruyama, Yumiko, Matsuoka, Ken-ichi, Nagafuji, Koji, Eto, Tetsuya, Tanaka, Takashi, Ohigashi, Hiroyuki, Nakamae, Hirohisa, Onizuka, Makoto, Fukuda, Takahiro, Atsuta, Yoshiko, and Yanada, Masamitsu
- Subjects
- *
ACUTE myeloid leukemia , *PROGNOSIS , *HEMATOPOIETIC stem cell transplantation , *ALLOCATION of organs, tissues, etc. , *CYCLOPHOSPHAMIDE , *OVERALL survival , *BRAIN death - Abstract
Haploidentical hematopoietic stem cell transplantation (haplo‐HCT) is an appropriate option when an HLA-matched related or unrelated donor is not available. Haplo-HCT using post-transplant cyclophosphamide (PTCy) is being increasingly performed worldwide due to its effective suppression of GVHD and its safety. We conducted a large nationwide cohort study to retrospectively analyze 366 patients with acute myeloid leukemia undergoing haplo‐HCT with PTCy between 2010 and 2019 and to identify prognostic factors. A multivariate Cox analysis revealed that an older recipient age (≥60 years), a male donor to a male recipient, a cytomegalovirus IgG-negative donor to a cytomegalovirus IgG-positive recipient, a poor cytogenetic risk, a noncomplete remission status at the time of transplantation, and a history of HCT were independently associated with worse overall survival (OS). Based on each hazard ratio, these factors were scored (1–2 points) and stratified by their total score into three groups: favorable (0–1 points), intermediate (2–3 points), and poor (4 points or more) groups, and 2-year OS rates were 79.9%, 49.2%, and 25.1%, respectively (P < 0.001). The present study revealed significant prognostic factors in haplo‐HCT with PTCy, and a scoring system based on these factors may be used to predict outcomes. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. Advantages of peripheral blood stem cells from unrelated donors versus bone marrow transplants in outcomes of adult acute myeloid leukemia patients.
- Author
-
Jo, Tomoyasu, Arai, Yasuyuki, Kondo, Tadakazu, Mizuno, Shohei, Hirabayashi, Shigeki, Inamoto, Yoshihiro, Doki, Noriko, Fukuda, Takahiro, Ozawa, Yukiyasu, Katayama, Yuta, Kanda, Yoshinobu, Fukushima, Kentaro, Matsuoka, Ken-ichi, Takada, Satoru, Sawa, Masashi, Ashida, Takashi, Onizuka, Makoto, Ichinohe, Tatsuo, Atsuta, Yoshiko, and Kanda, Junya
- Subjects
- *
ACUTE myeloid leukemia , *BLOOD cells , *BONE marrow , *STEM cells , *TREATMENT effectiveness - Abstract
In allogeneic stem cell transplantation, unrelated donors are chosen in cases where appropriate related donors are not available. Peripheral blood stem cells (PBSCs) are more often selected as a graft source than bone marrow (BM). However, the prognostic benefits of PBSCs versus BM transplants from unrelated donors have not been carefully examined in patients with acute myeloid leukemia (AML). This study compared outcomes of adult AML patients who underwent unrelated PBSC and BM transplantation, evaluating post-transplant complications, including engraftment, graft-versus-host disease (GVHD) and infections, and determined subgroups of patients who are most likely to benefit from unrelated PBSCs compared with BM transplants. The authors analyzed 2962 adult AML patients who underwent unrelated PBSC or BM transplants between 2011 and 2018 (221 PBSC and 2741 BM) using the Japanese nationwide registry database, in which graft source selection is not skewed toward PBSCs. In 49.7% of patients, disease status at transplantation was first complete remission (CR1). In 57.1% of cases, HLA-matched donors were selected. Myeloablative conditioning was performed in 75.1% of cases, and anti-thymocyte globulin (ATG) was added to conditioning in 10.5%. Multivariate analyses showed a trend toward favorable non-relapse mortality (NRM) in PBSC recipients compared with BM recipients (hazard ratio [HR], 0.731, P = 0.096), whereas overall survival (OS) (HR, 0.959, P = 0.230) and disease-free survival (DFS) (HR, 0.868, P = 0.221) were comparable between PBSC and BM recipients. Although the rate of chronic GVHD (cGVHD) was significantly higher in PBSC patients (HR, 1.367, P = 0.016), NRM was not increased, mainly as a result of significantly reduced risk of bacterial infections (HR, 0.618, P = 0.010), reflecting more prompt engraftments in PBSC recipients. Subgroup analyses revealed that PBSC transplantation was advantageous in patients transplanted at CR1 and in those without ATG use. PBSC recipients experienced significantly better OS and/or DFS compared with BM recipients in this patient group. The authors' results confirmed the overall safety of unrelated PBSC transplantation for adult AML patients and suggested an advantage of PBSCs, especially for those in CR1. Further optimization of the prophylactic strategy for cGVHD is required to improve the overall outcome in transplantation from unrelated PBSC donors. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
28. Outcome and Risk Factors for Therapy-Related Myeloid Neoplasms Treated with Allogeneic Stem Cell Transplantation in Japan.
- Author
-
Kida, Michiko, Usuki, Kensuke, Uchida, Naoyuki, Fukuda, Takahiro, Katayama, Yuta, Kondo, Tadakazu, Eto, Tetsuya, Matsuoka, Ken-ichi, Matsuhashi, Yoshiko, Ota, Shuichi, Sawa, Masashi, Miyamoto, Toshihiro, Ichinohe, Tatsuo, Kimura, Takafumi, Atsuta, Yoshiko, Takami, Akiyoshi, Miyazaki, Yasushi, Yano, Shingo, Ishiyama, Ken, and Yanada, Masamitsu
- Subjects
- *
STEM cell transplantation , *ACUTE myeloid leukemia , *CHRONIC leukemia , *TUMORS , *MYELODYSPLASTIC syndromes - Abstract
This study aimed to investigate allogeneic hematopoietic cell transplantation (HCT) outcomes and risk factors in adult patients with therapy-related myeloid neoplasm (t-MN) using Japanese registry data. Between 2002 and 2012, a total 12,169 adult patients underwent HCT for acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML). Of these, 565 with t-MN were identified. The median patient age was 54 years (range, 16 to 80 years). Three hundred and ninety-eight patients had AML, 154 had MDS, and 13 had CMML. Lymphoma and breast cancer were the major previous malignancies. Favorable karyotypes were detected in 84 patients, and poor karyotypes were identified in 235. Two-thirds (66%) of the patients were in nonremission at HCT. Overall survival at 3 years in patients with t-MN was 31% (95% confidence interval [CI], 27% to 35%), equivalent to that in those with secondary MN (32%; 95% CI, 30% to 34%), and 44% in the de novo cohort (95% CI, 43% to 45%). The cumulative incidence of relapse and nonrelapse mortality at 3 years was 40% and 33%, respectively. The outcomes of HCT for t-MN in Japan were comparable to those in large-scale studies in Europe and the United States. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
29. Favorable Effect of Cytomegalovirus Reactivation on Outcomes in Cord Blood Transplant and Its Differences Among Disease Risk or Type.
- Author
-
Yokoyama, Hisayuki, Takenaka, Katsuto, Nishida, Tetsuya, Seo, Sachiko, Shinohara, Akihito, Uchida, Naoyuki, Tanaka, Masatsugu, Takahashi, Satoshi, Onizuka, Makoto, Kozai, Yasuji, Yasuhiro, Sugio, Ozawa, Yukiyasu, Katsuoka, Yuna, Doki, Noriko, Sawa, Masashi, Kimura, Takafumi, Kanda, Junya, Fukuda, Takahiro, Atsuta, Yoshiko, and Nakasone, Hideki
- Subjects
- *
CORD blood , *CYTOMEGALOVIRUSES , *HUMAN cytomegalovirus , *ACUTE myeloid leukemia , *CORD blood transplantation , *LYMPHOBLASTIC leukemia , *MYELODYSPLASTIC syndromes , *ALEMTUZUMAB - Abstract
• Effect of cytomegalovirus (CMV) reactivation on cord blood transplant (CBT) was studied. • CMV reactivation is associated with improved overall survival (OS) in AML and MDS. • CMV reactivation is associated with improved OS in high disease risk cases. • CMV reactivation reduced the risk of relapse in MDS and high disease risk cases. • CMV reactivation adversely affected nonrelapse mortality in standard risk cases. The effects of cytomegalovirus (CMV) reactivation on cord blood transplant (CBT) are unclear. We assessed the effect of CMV reactivation in adult single-unit CBT without in vivo T cell depletion. Of 3147 eligible cases, 2052 were acute myeloid leukemia (AML), 643 acute lymphoblastic leukemia (ALL), and 452 myelodysplastic syndrome (MDS). CMV reactivation up to 100 days after CBT was associated with better overall survival (OS) compared with no reactivation cases (57.3% versus 52.6% at 3 years after CBT), whereas nonrelapse mortality (NRM) was increased in ALL (16.2% versus 8.9%) and standard disease risk (17.1% versus 10.6%, P =.014) by CMV reactivation. On multivariate analysis, CMV reactivation had favorable effects on relapse in MDS (hazard ratio [HR],.55; P =.044) and high disease risk (HR,.77; P =.047). In NRM, only standard-risk cases showed adverse effects of CMV reactivation (HR, 1.56; P =.026). OS was significantly improved with CMV reactivation in a subgroup of patients with AML (HR,.84; P =.044), MDS (HR,.68; P =.048), and high disease risk (HR,.81; P =.013). This favorable effect of CMV reactivation on OS in AML and high disease risk cases was maintained even after considering the effect of grades II to IV acute graft-versus-host disease. Thus, CMV reactivation might have beneficial or adverse effects on relapse, NRM, and OS, depending on the disease type or disease risk. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
30. Impact of HLA Allele Mismatch at HLA-A, -B, -C, and -DRB1 in Single Cord Blood Transplantation.
- Author
-
Yokoyama, Hisayuki, Morishima, Yasuo, Fuji, Shigeo, Uchida, Naoyuki, Takahashi, Satoshi, Onizuka, Makoto, Tanaka, Masatsugu, Yuju, Ohno, Eto, Tetsuya, Ozawa, Yukiyasu, Takada, Satoru, Takanashi, Minoko, Kato, Koji, Kanda, Yoshinobu, Ichinohe, Tatsuo, Atsuta, Yoshiko, and Kanda, Junya
- Subjects
- *
CORD blood transplantation , *ALEMTUZUMAB , *ALLELES , *CORD blood , *ACUTE myeloid leukemia , *GRAFT versus host disease , *LYMPHOBLASTIC leukemia - Abstract
• HLA-A, -B, -C, and -DRB1 allele mismatch effects were examined in 4050 cases of cord blood transplants. • Overall survival (OS) deteriorated in HLA 5-allele and higher mismatch in adult cord blood transplantation (CBT). • OS deteriorated in HLA 4-allele and higher mismatch in pediatric CBT. • In adult cases, 8/8 match mitigated severe acute graft-versus-host disease (GVHD) but increased the relapse rate. • In pediatric cases, 8/8 match and 1-allele mismatch mitigated acute GVHD. The impact of allele-level HLA mismatch on outcomes of cord blood transplantation has not been well established. We retrospectively analyzed the effects of HLA allele matching at HLA-A, -B, -C, and -DRB1 in cord blood transplantation for acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome. In multivariate analysis, overall survival (OS) significantly deteriorated in the 4-allele or higher mismatch in pediatric cases (hazard ratio, 1.8 for 4/8 match [reference, 6/8 match] and 2.85 for 3-1/8 match) and the 5-allele or higher mismatch in adult cases (hazard ratio, 1.23 for 3-0/8 match). Incidence of grade Ⅲ to Ⅳ acute graft-versus-host disease was low in the 8/8 match and 1-allele mismatch in pediatric cases (hazard ratio, 0.19 for 8/8 match and 0.41 for 7/8 match) and the 8/8 match in adult cases (hazard ratio, 0.41 for 8/8 match). On the other hand, a higher incidence of relapse was noted in the 8/8 match in adults (hazard ratio, 1.53). The incidence of neutrophil and platelet engraftment decreased in the 3-allele or higher mismatch in adults. In subgroup analysis of graft-versus-host disease prophylaxis in adult cases, a deteriorating effect on OS of HLA 5-allele or higher mismatch was more significant in cases with calcineurin inhibitor with methotrexate than with mycophenolate mofetil. These results suggest that allele-level HLA mismatch affects the outcomes of cord blood transplantation. Information on HLA allele matching at HLA-A, -B, -C, and -DRB1 may be useful for cord blood unit selection. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
31. Conditioning Intensity for Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients with Poor-Prognosis Cytogenetics in First Complete Remission.
- Author
-
Konuma, Takaaki, Kondo, Tadakazu, Mizuno, Shohei, Doki, Noriko, Aoki, Jun, Fukuda, Takahiro, Tanaka, Masatsugu, Sawa, Masashi, Katayama, Yuta, Uchida, Naoyuki, Ozawa, Yukiyasu, Morishige, Satoshi, Matsuoka, Ken-ichi, Ichinohe, Tatsuo, Onizuka, Makoto, Kanda, Junya, Atsuta, Yoshiko, and Yanada, Masamitsu
- Subjects
- *
ACUTE myeloid leukemia , *CELL transplantation , *TOTAL body irradiation , *ALEMTUZUMAB , *CYTOGENETICS , *PROGNOSIS , *COMORBIDITY - Abstract
• In comparison with reduced-intensity conditioning, myeloablative conditioning (MAC) reduced leukemia-related mortality and improved overall survival for patients with cytogenetically poor-risk acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation (HCT) during first complete remission. • In the subgroup analysis, these results applied to patients aged 16 to 59 years, with HCT-comorbidity index scores ≥3 and with cytogenetic remission. • Among MAC regimens, there was a trend for worse survival and nonrelapse mortality with the busulfan/fludarabine-based regimen compared with the total body irradiation-based regimen. The optimal intensity of conditioning regimen may be dependent on not only age and comorbidities but also disease characteristics and risk of relapse after allogeneic hematopoietic cell transplantation (HCT). We, therefore, analyzed the transplant outcomes of 840 adult patients with cytogenetically poor-risk acute myeloid leukemia (AML) in first complete remission (CR1) who received first allogeneic HCT with either myeloablative conditioning (MAC; n = 652) or reduced-intensity conditioning (RIC; n = 188) between 2006 and 2017. The median age at HCT was 50.5 years (range: 16 to 77 years). The multivariate analysis showed that patients receiving MAC had a significantly higher overall survival and lower leukemia-related mortality than those receiving RIC (P =.011 and P =.025, respectively). In the subgroup analysis, these results applied to patients aged 16 to 59 years, with HCT-comorbidity index scores ≥3, and with cytogenetic remission. Among MAC regimens, there was a trend for worse survival and nonrelapse mortality with the busulfan/fludarabine-based regimen compared with the total body irradiation (TBI) ≥8 Gy-based regimen (P =.082 and P =.062, respectively), whereas the busulfan/cyclophosphamide-based regimen and the fludarabine/melphalan-based regimen had similar outcomes with the TBI-based regimen. These data suggest that MAC is preferable to RIC for patients with cytogenetically poor-risk AML undergoing allogeneic HCT in CR1. Image, graphical abstract [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
32. Time-Varying Effects of Graft Type on Outcomes for Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
- Author
-
Yanada, Masamitsu, Konuma, Takaaki, Yamasaki, Satoshi, Kuwatsuka, Yachiyo, Masuko, Masayoshi, Tanaka, Masatsugu, Ozawa, Yukiyasu, Toya, Takashi, Fukuda, Takahiro, Ota, Shuichi, Sawa, Masashi, Uchida, Naoyuki, Nakamae, Hirohisa, Eto, Tetsuya, Kanda, Junya, Takanashi, Minoko, Kanda, Yoshinobu, Atsuta, Yoshiko, and Yano, Shingo
- Subjects
- *
ACUTE myeloid leukemia , *CORD blood transplantation , *CELL transplantation , *BONE marrow transplantation , *STEM cell transplantation , *ALEMTUZUMAB - Abstract
• This study aimed to investigate time-varying effects of graft type on allogeneic HCT outcomes for AML. • RFS and OS were worse for related PBSCT and UCBT than for related BMT. • Adverse impact of UCBT was observed only during the early phase of transplant. • Adverse impact of related PBSCT continued even after 2 years post-transplant. • Our findings raise concerns regarding the increased risk of late nonrelapse mortality with the use of PBSC grafts. This study aimed to investigate time-varying effects of graft type on outcomes for patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant. For this purpose we analyzed 3952 patients, 720 of whom underwent matched related bone marrow transplantation (BMT), 1004 matched related peripheral blood stem cell transplantation (PBSCT), 856 matched unrelated BMT, and 1372 umbilical cord blood transplantation (UCBT) during complete remission. The 4-year relapse-free survival (RFS) rates were 59.1%, 52.8%, 59.5%, and 50.6%, respectively. Compared with related BMT, related PBSCT, unrelated BMT, and UCBT were associated with higher risk of nonrelapse mortality and unrelated BMT and UCBT with lower risk of relapse. As a result, both RFS and overall survival were comparable between related BMT and unrelated BMT but were worse for related PBSCT and UCBT than for related BMT. Adverse impact of UCBT was observed only during the early phase of transplant, whereas that of related PBSCT continued even after 2 years post-transplant. Our findings raise concerns about the increased risk of late nonrelapse mortality with the use of PBSC grafts and suggest that related BMT is preferable to related PBSCT; matched unrelated BMT is the next choice in the absence of a matched related donor. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
33. Risk Stratification and Prognosticators of Acute Myeloid Leukemia with Myelodysplasia-Related Changes in Patients Undergoing Allogeneic Stem Cell Transplantation: A Retrospective Study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation
- Author
-
Harada, Kaito, Konuma, Takaaki, Machida, Shinichiro, Mori, Jinichi, Aoki, Jun, Uchida, Naoyuki, Ohashi, Kazuteru, Fukuda, Takahiro, Tanaka, Masatsugu, Ikegame, Kazuhiro, Ozawa, Yukiyasu, Iwato, Koji, Eto, Tetsuya, Onizuka, Makoto, Ichinohe, Tatsuo, Atsuta, Yoshiko, and Yano, Shingo
- Subjects
- *
STEM cell transplantation , *ACUTE myeloid leukemia , *CELL transplantation , *TEAMS in the workplace , *MYELODYSPLASTIC syndromes , *ALEMTUZUMAB - Abstract
• The transplant outcomes of AML-MRC were generally inferior than those of AML-NOS. • Our risk stratification can aid in elucidating the diverse outcomes of AML-MRC. • Grades I to II acute GVHD is associated with better survival in patients with AML-MRC. Although the prognosis of acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) is worse than that of AML not otherwise specified (AML-NOS), transplantation outcomes and prognosticators of AML-MRC patients undergoing allogeneic stem cell transplantation (allo-SCT) remain unclear. Transplantation outcomes of AML-MRC (n = 4091) were compared with those of AML-NOS (n = 3964) in patients who underwent allo-SCT between 2003 and 2016 using a nationwide registration database. The 3-year overall survival (OS; 35.5% versus 50.6%) was lower and the relapse (42.3% versus 32.1%) and nonrelapse mortality (26.3% versus 22.0%) rates were higher in the AML-MRC group than in the AML-NOS group. Based on the hierarchical AML-MRC classification, myelodysplasia as the sole criterion was associated with better OS compared with AML-NOS, whereas monosomal or complex karyotype and −5/del(5q) were associated with poor OS. A history of myelodysplastic syndrome and −7/del(7q) did not affect OS. Accordingly, AML-MRC with complex karyotype or −5/del(5q) and that with monosomal karyotype were classified as intermediate and high risks, respectively, whereas the remaining cases were classified as low risk. The 3-year OS rates were 50.7%, 36.9%, and 13.8% in the low-, intermediate-, and high-risk groups, respectively (P <.001). Risk classification, older age, and low performance status score were significant risk factors for survival in AML-MRC, independently of the disease status. Grades I to II acute graft-versus-host disease significantly reduced the 3-year relapse (24.7% versus 31.6%), leading to better survival (hazard ratio,.64). Our prognostic risk stratification can potentially aid in elucidating the diverse transplantation outcomes in patients with AML-MRC. Image, graphical abstract [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
34. Hematopoietic Cell Transplantation for Acute Panmyelosis with Myelofibrosis: A Retrospective Study in Japan.
- Author
-
Konuma, Takaaki, Kondo, Tadakazu, Kawata, Takahito, Iwato, Koji, Sato, Yuji, Mori, Takehiko, Ohashi, Kazuteru, Nakazawa, Hideyuki, Sugahara, Hiroyuki, Ago, Hiroatsu, Eto, Tetsuya, Imamura, Yutaka, Fukuda, Takahiro, Kanda, Yoshinobu, Atsuta, Yoshiko, and Yano, Shingo
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *MYELOFIBROSIS , *GRAFT versus host disease , *MYELOID leukemia , *BONE marrow - Abstract
Highlights • Patients with APMF have a poor outcome because of high relapse rates even after syngeneic and allogeneic HCT. • Allogeneic HCT offered a curative option for APMF. Abstract Acute panmyelosis with myelofibrosis (APMF) is a rare subtype of acute myeloid leukemia characterized by acute onset of cytopenias and bone marrow fibrosis in the absence of splenomegaly. Because the prognosis of APMF is extremely poor even after chemotherapy, hematopoietic cell transplantation (HCT) has been used to treat APMF. However, the outcome after HCT for APMF remains unclear. To evaluate the outcomes and prognostic factors after HCT as a therapeutic modality for APMF, we retrospectively analyzed the Japanese registration data of 40 APMF patients who received allogeneic and syngeneic HCT between 2005 and 2015. The median age at HCT was 53.5 years (range, 16 to 70). The disease status at HCT was first complete remission (CR1) in 13 patients (33%). The probability of overall survival and the cumulative incidence of relapse at 3 years were 24% and 59%, respectively. Univariate analysis identified that female sex and disease status CR1 at the time of HCT were significantly associated with higher overall survival. Although APMF patients have a poor long-term prognosis even after syngeneic and allogeneic HCT, these data suggested that allogeneic HCT offered a curative option for APMF. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
35. Additional Cytogenetic Abnormalities with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia on Allogeneic Stem Cell Transplantation in the Tyrosine Kinase Inhibitor Era.
- Author
-
Akahoshi, Yu, Kako, Shinichi, Ohta, Shuichi, Eto, Tetsuya, Tanaka, Junji, Atsuta, Yoshiko, Mizuta, Shuichi, Shimizu, Hiroaki, Uchida, Naoyuki, Fukuda, Takahiro, Kanamori, Heiwa, Onizuka, Makoto, Ozawa, Yukiyasu, and Ohashi, Kazuteru
- Subjects
- *
LYMPHOBLASTIC leukemia , *STEM cell transplantation , *PROTEIN-tyrosine kinase inhibitors , *CANCER chemotherapy , *HEMATOPOIETIC stem cell transplantation , *ACUTE myeloid leukemia - Abstract
Highlights • The impact of ACAs in Ph+ ALL is not well understood in the TKI era. • ACAs did not have a significant prognostic impact on transplantation outcomes. • The presence of +8 may be associated with an increased risk of relapse. Abstract Cytogenetic abnormalities are well known and powerful independent prognostic factors for various hematologic disorders. Although the combination of chemotherapy with tyrosine kinase inhibitor (TKI) is now considered the standard of care in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia, little is known about the impact of additional cytogenetic abnormalities (ACAs). Therefore, we retrospectively evaluated 1375 adult patients who underwent their first allogeneic hematopoietic stem cell transplantation in the TKI era. In this study, 224 patients had ACAs (16.3%). The ACAs that were seen in more than 20 cases (1.5%) were as follows: -7, der(22), der(9), +8, and +X. Overall survival at 4 years was 56.9% (95% confidence interval [CI], 49.4% to 63.7%) in the group with ACAs and 60.5% (95% CI, 57.3% to 63.5%) in the group without ACAs (P =.266). The cumulative incidence of relapse at 4 years was 28.9% (95% CI, 22.6% to 35.6%) in the group with ACAs and 21.9% (95% CI, 19.4% to 24.6%) in the group with Ph alone (P =.051). In multivariate analyses there were no statistically significant differences in the risk of overall mortality or risk of relapse between the groups with and without ACAs. In the subgroup analyses of specific ACAs, although the presence of +8 was associated with a higher relapse rate in univariate and multivariate analyses, no specific ACA was associated with poor overall survival. Further studies will be needed to verify the impact of specific ACAs on transplantation outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
36. Allogeneic Hematopoietic Stem Cell Transplantation for Adolescents and Young Adults with Acute Myeloid Leukemia.
- Author
-
Tomizawa, Daisuke, Tanaka, Shiro, Kondo, Tadakazu, Hashii, Yoshiko, Arai, Yasuyuki, Kudo, Kazuko, Taga, Takashi, Fukuda, Takahiro, Goto, Hiroaki, Inagaki, Jiro, Koh, Katsuyoshi, Ohashi, Kazuteru, Ozawa, Yukiyasu, Inoue, Masami, Kato, Koji, Tanaka, Junji, Atsuta, Yoshiko, Adachi, Souichi, and Ishida, Hiroyuki
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *MYELOID leukemia , *SURVIVAL , *BLOOD donors , *TRANSPLANTATION of organs, tissues, etc. - Abstract
Few reports have focused on adolescent and young adult (AYA) patients with acute myeloid leukemia (AML) treated with hematopoietic stem cell transplantation (HSCT). We performed a retrospective analysis based on data obtained from a Japanese nationwide registration database to compare HSCT outcomes in AYA patients with AML with those in children with AML. An analysis of the 2973 patients with de novo AML who received allogeneic HSCT from 1990 to 2013 showed inferior 5-year overall survival (OS) (54% versus 58%, P < .01) and increased treatment-related mortality (TRM) (16% versus 13%, P = .02) in AYA patients. Multivariate analysis for both OS and TRM showed a significant negative impact on AYAs. However, the negative impact of older age lost its significance in an additional analysis focusing on 1407 recent transplant recipients with high-resolution HLA typing (2000 to 2013). Finally, we analyzed the impact of transplantation center type on HSCT outcomes in 317 adolescent patients (15 to 18 years old) and found no difference in outcomes between patients treated at a pediatric or an adult hospital. Higher age was a strong predictive factor for inferior OS resulting from increased TRM, which can be eliminated with better donor selection using high-resolution HLA typing. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
37. Comparison of Autologous and Unrelated Transplants for Cytogenetically Normal Acute Myelogenous Leukemia.
- Author
-
Mizutani, Motonori, Takami, Akiyoshi, Hara, Masahiko, Mizuno, Shohei, Yanada, Masamitsu, Chou, Takaaki, Uchiyama, Hitoji, Ohashi, Kazuteru, Miyamoto, Toshihiro, Ozawa, Yukiyasu, Imataki, Osamu, Kobayashi, Naoki, Uchida, Naoyuki, Kanamori, Heiwa, Kamimura, Tomohiko, Eto, Tetsuya, Onizuka, Makoto, Tanaka, Junji, Atsuta, Yoshiko, and Yano, Shingo
- Subjects
- *
ACUTE myeloid leukemia , *BONE marrow , *STEM cell transplantation , *CYTOGENETICS , *STEM cell donors - Abstract
Allogeneic stem cell transplantation (SCT) from an HLA-matched sibling donor (MSD) is a postremission treatment that offers a potential cure for adults with cytogenetically normal (CN) acute myelogenous leukemia (AML) in first complete remission (CR1). The best alternative in the absence of an MSD remains unclear, however. The aim of this study was to retrospectively compare the outcomes of autologous peripheral blood stem cell transplantation (auto-PBSCT; n = 177) and allogeneic bone marrow transplantation (BMT) from an HLA-matched unrelated donor (MUD; n = 173) in adult patients with CN-AML/CR1. Both the multivariate analysis (hazard ratio [HR], 1.18; 95% confidence interval [CI], 0.71 to 1.97; P = .53) and propensity score models (HR, 1.40; 95% CI, 0.80 to 2.43; P = .24) indicated that the leukemia-free survival (LFS) rate of auto-PBSCT was not significantly different from that of MUD-BMT. These results suggest that in the absence of an available MSD, auto-PBSCT remains a viable alternative as postremission therapy in patients with CN-AML/CR1. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
38. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients with Abnormalities of the Short Arm of Chromosome 17.
- Author
-
Mori, Jinichi, Yanada, Masamitsu, Uchida, Naoyuki, Fukuda, Takahiro, Sakura, Toru, Hidaka, Michihiro, Watakabe-Inamoto, Kyoko, Kanamori, Heiwa, Ogawa, Hiroyasu, Ichinohe, Tatsuo, Tanaka, Junji, Atsuta, Yoshiko, and Yano, Shingo
- Subjects
- *
HEALTH outcome assessment , *HEMATOPOIETIC stem cell transplantation , *ACUTE myeloid leukemia , *CHROMOSOME abnormalities , *PROGRESSION-free survival , *PATIENTS - Abstract
We retrospectively analyzed a Japanese nationwide database to elucidate the impact of abnormalities in the short arm of chromosome 17 (abnl[17p]) on the outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with acute myeloid leukemia. Of 10,923 patients, 262 (2.4%) had abnl(17p), 235 of whom were classified into the poor cytogenetic risk group according to the National Comprehensive Cancer Network criteria. The median follow-up period was 1425 days. In abnl(17p) versus non-abnl(17p) patients of poor cytogenetic risk group, overall survival (OS), disease-free survival, cumulative incidence of disease relapse, and nonrelapse mortality rates at 5 years after allo-HSCT were 9.2% versus 27.4%, 7.8% versus 25.0%, 66.6% versus 49.4%, and 25.6% versus 25.6%, respectively. In contrast to the other types of abnl(17p), isochromosome 17q rarely encompassed the poor cytogenetic risk traits and did not adversely affect OS. Among the abnl(17p) patients, male sex, nonremission disease status at transplantation, and poor cytogenetic risk group were significantly associated with shorter OS. In conclusion, the presence of an abnl(17p) negatively affects allo-HSCT outcomes, which are influenced by the type of abnormality. Prompt initiation of allo-HSCT during complete remission may improve outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
39. Allogeneic Hematopoietic Cell Transplantation for Leukemic Transformation Preceded by Philadelphia Chromosome–Negative Myeloproliferative Neoplasms: A Nationwide Survey by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation
- Author
-
Takagi, Shinsuke, Masuoka, Kazuhiro, Uchida, Naoyuki, Kurokawa, Mineo, Nakamae, Hirohisa, Imada, Kazunori, Iwato, Koji, Ichinohe, Tatsuo, Atsuta, Yoshiko, Takami, Akiyoshi, and Yano, Shingo
- Subjects
- *
LEUKEMIA treatment , *MYELOID leukemia , *HEMATOPOIETIC stem cell transplantation , *MYELOPROLIFERATIVE neoplasms , *DISEASE incidence , *RETROSPECTIVE studies , *MORTALITY , *THERAPEUTICS - Abstract
To clarify the outcome of allogeneic hematopoietic cell transplantation (HCT) for leukemic transformation (LT) preceded by Philadelphia chromosome–negative (Ph-neg) myeloproliferative neoplasms (MPNs), we conducted a retrospective study using the national registry database of the Japan Society for Hematopoietic Cell Transplantation. From 2000 to 2013, 39 patients underwent their first allogeneic HCT with related bone marrow or peripheral blood stem cells (n = 8), unrelated bone marrow (n = 15), and unrelated umbilical cord blood (n = 16). The median patient age was 57 years. The underlying Ph-neg MPNs included 21 cases of essential thrombocythemia, 11 cases of primary myelofibrosis, and 7 cases of polycythemia vera. The median interval between the diagnosis of LT and transplantation was 134 days. Thirty-two cases (82%) were not in remission at the time of transplantation. The 2-year overall survival rate was 29.2% (95% confidence interval [CI], 15.5% to 44.3%). The median follow-up of the surviving patients was 1989.5 days (range, 285 to 3270). The cumulative incidences of relapse and nonrelapse mortality at 2 years were 34.4% (95% CI, 19.6% to 49.8%) and 34.2% (95% CI, 19.6% to 49.4%), respectively. The study results suggested that allogeneic HCT provides long-term survival in approximately one-third of patients with LT preceded by Ph-neg MPNs. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
40. Comparison of Outcomes for Pediatric Patients With Acute Myeloid Leukemia in Remission and Undergoing Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Based on Either Intravenous Busulfan or Total Body Irradiation: A Report From the Japanese Society for Hematopoietic Cell Transplantation
- Author
-
Ishida, Hiroyuki, Kato, Motohiro, Kudo, Kazuko, Taga, Takashi, Tomizawa, Daisuke, Miyamura, Takako, Goto, Hiroaki, Inagaki, Jiro, Koh, Katsuyoshi, Terui, Kiminori, Ogawa, Atsushi, Kawano, Yoshifumi, Inoue, Masami, Sawada, Akihisa, Kato, Koji, Atsuta, Yoshiko, Yamashita, Takuya, and Adachi, Souichi
- Subjects
- *
ACUTE myeloid leukemia treatment , *PEDIATRICS , *HEMATOPOIETIC stem cell transplantation , *HEALTH outcome assessment , *HOMOGRAFTS , *BUSULFAN - Abstract
Pediatric patients with acute myeloid leukemia (AML) mainly receive myeloablative conditioning regimens based on busulfan (BU) or total body irradiation (TBI) before allogeneic hematopoietic cell transplantation (allo-HCT); however, the optimal conditioning regimen remains unclear. To identify which of these regimens is better for pediatric patients, we performed a retrospective analysis of nationwide registration data collected in Japan between 2006 and 2011 to assess the outcomes of patients receiving these regimens before a first allo-HCT. Myeloablative conditioning regimens based on i.v. BU (i.v. BU-MAC) (n = 69) or TBI (TBI-MAC) (n = 151) were compared in pediatric AML patients in first or second complete remission (CR1/CR2). The incidences of sinusoid obstruction syndrome, acute and chronic graft-versus-host disease, and early nonrelapse mortality (NRM) before day 100 were similar for both conditioning groups; however, the incidence of bacterial infection during the acute period was higher in the TBI-MAC group ( P = .008). Both groups showed a similar incidence of NRM, and there was no significant difference in the incidence of relapse between the groups. Univariate and multivariate analyses revealed no significant differences in the 2-year relapse-free survival rates for the i.v. BU-MAC and TBI-MAC groups in the CR1/CR2 setting (71% versus 67%, P = .36; hazard ratio, .73; 95% CI, .43 to 1.24, respectively). TBI-MAC was no better than i.v. BU-MAC for pediatric AML patients in remission. Although this retrospective registry-based analysis has several limitations, i.v. BU-MAC warrants further evaluation in a prospective trial. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
41. Effect of Granulocyte Colony–Stimulating Factor–Combined Conditioning in Cord Blood Transplantation for Myelodysplastic Syndrome and Secondary Acute Myeloid Leukemia: A Retrospective Study in Japan.
- Author
-
Konuma, Takaaki, Takahashi, Satoshi, Uchida, Naoyuki, Kuwatsuka, Yachiyo, Yamasaki, Satoshi, Aoki, Jun, Onishi, Yasushi, Aotsuka, Nobuyuki, Ohashi, Kazuteru, Mori, Takehiko, Masuko, Masayoshi, Nakamae, Hirohisa, Miyamura, Kouichi, Kato, Koji, Atsuta, Yoshiko, Kato, Seiko, Asano, Shigetaka, Takami, Akiyoshi, and Miyazaki, Yasushi
- Subjects
- *
GRANULOCYTES , *COLONY-stimulating factors (Physiology) , *CORD blood transplantation , *MYELODYSPLASTIC syndromes , *ACUTE myeloid leukemia , *RETROSPECTIVE studies - Abstract
Granulocyte colony–stimulating factor (G-CSF) increases the susceptibility of dormant malignant or nonmalignant hematopoietic cells to cytarabine arabinoside (Ara-C) through the induction of cell cycle entry. Therefore, G-CSF–combined conditioning before allogeneic stem cell transplantation might positively contribute to decreased incidences of relapse and graft failure without having to increase the dose of cytotoxic drugs. We conducted a retrospective nationwide study of 336 adult patients with myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia (sAML) after single-unit cord blood transplantation (CBT) who underwent 4 different kinds of conditioning regimens: total body irradiation (TBI) ≥ 8 Gy + Ara-C/G-CSF + cyclophosphamide (CY) (n = 65), TBI ≥ 8 Gy + Ara-C + CY (n = 119), TBI ≥ 8 Gy + other (n = 104), or TBI < 8 Gy or non-TBI (n = 48). The TBI ≥ 8 Gy + Ara-C/G-CSF + CY regimen showed significantly higher incidence of neutrophil engraftment (hazard ratio, 1.52; 95% confidence interval [CI], 1.10 to 2.08; P = .009) and lower overall mortality (hazard ratio, .46; 95% CI, .26 to .82; P = .008) rates compared with those without a G-CSF regimen. This retrospective study shows that the G-CSF–combined conditioning regimen provides better engraftment and survival results in CBT for adults with MDS and sAML. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
42. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia Patients with Central Nervous System Involvement.
- Author
-
Aoki, Jun, Ishiyama, Ken, Taniguchi, Shuichi, Fukuda, Takahiro, Ohashi, Kazuteru, Ogawa, Hiroyasu, Kanamori, Heiwa, Eto, Tetsuya, Iwato, Koji, Sakamaki, Hisashi, Morishima, Yasuo, Nagamura, Tokiko, Atsuta, Yoshiko, and Takami, Akiyoshi
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *ACUTE myeloid leukemia , *CENTRAL nervous system diseases , *CANCER cells , *GRAFT versus host disease , *HEALTH outcome assessment - Abstract
Central nervous system (CNS) involvement in adult acute myeloid leukemia (AML) is rare and associated with poor outcomes. Therefore, CNS involvement in AML is an indicator for allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, the impact of CNS involvement in AML on the outcome of allo-HSCT remains unclear. We performed a large-scale nationwide retrospective analysis to elucidate the outcomes of allo-HSCT on AML with CNS involvement (CNS+AML). Clinical data were collected from a registry database of the Japan Society for Hematopoietic Cell Transplantation. CNS involvement was defined as the infiltration of leukemia cells into the CNS or myeloid sarcoma in the CNS identified at any time from diagnosis to transplantation. One hundred fifty-seven patients with CNS+AML underwent allo-HSCT between 2006 and 2011. The estimated overall survival, cumulative incidence of relapse and nonrelapse mortality at 2 years for CNS+AML (51.2%, 30.2%, and 14.5%, respectively) were comparable with those for AML without CNS involvement (48.6%, 27.4%, and 22.0%, respectively). Univariate and multivariate analyses indicated that the development of chronic graft-versus-host disease, disease status, and cytogenetic risk category were independent prognostic factors for overall survival for CNS+AML. These results suggest that allo-HSCT may improve outcomes in patients with CNS+AML. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
43. Donor Lymphocyte Infusion for the Treatment of Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation
- Author
-
Takami, Akiyoshi, Yano, Shingo, Yokoyama, Hiroki, Kuwatsuka, Yachiyo, Yamaguchi, Takuhiro, Kanda, Yoshinobu, Morishima, Yasuo, Fukuda, Takahiro, Miyazaki, Yasushi, Nakamae, Hirohisa, Tanaka, Junji, Atsuta, Yoshiko, and Kanamori, Heiwa
- Subjects
- *
LYMPHOCYTES , *ACUTE myeloid leukemia , *HEMATOPOIETIC stem cell transplantation , *RETROSPECTIVE studies , *BONE marrow transplantation - Abstract
Because the efficacy of donor lymphocyte infusion (DLI) for acute myeloid leukemia (AML) relapse after allogeneic hematopoietic stem cell transplantation (HSCT) remains uncertain, especially in the Asian population, a nationwide registry study was retrospectively performed by the Adult AML Working Group of the Japan Society for Hematopoietic Cell Transplantation to identify the factors affecting the patient survival after DLI. Among 143 adult AML patients who received DLI for the treatment of first hematological relapse after HSCT, the overall survival rates at 1 year, 2 years, and 5 years were 32% ± 4%, 17% ± 3%, and 7% ± 3%, respectively. Complete remission (CR) at the time of DLI, which was obtained in 8% of the patients, was the strongest predictive factor for survival after DLI. Therefore, long-term survival after DLI was achieved almost exclusively in patients who successfully achieved a CR before DLI, indicating the limited efficacy of DLI in a minority of patients. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
44. Hematopoietic stem cell transplantation for pediatric acute myeloid leukemia patients with KMT2A rearrangement; A nationwide retrospective analysis in Japan.
- Author
-
Miyamura, Takako, Kudo, Kazuko, Tabuchi, Ken, Ishida, Hiroyuki, Tomizawa, Daisuke, Adachi, Souichi, Goto, Hiroaki, Yoshida, Nao, Inoue, Masami, Koh, Katsuyoshi, Sasahara, Yoji, Fujita, Naoto, Kakuda, Harumi, Noguchi, Maiko, Hiwatari, Mitsuteru, Hashii, Yoshiko, Kato, Koji, Atsuta, Yoshiko, and Okamoto, Yasuhiro
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *ACUTE myeloid leukemia , *RETROSPECTIVE studies - Abstract
• Three-year OS and DFS rates of KMT2A -rearrageged pediatric AML was 52.1% and 46.7%. • Complete remission at HSCT was the most significant prognostic factor. • Supportive therapy and considering donor source might improve treatment outcomes. Pediatric acute myeloid leukemia (AML) with KMT2A rearrangement is detected in 15–20% of all pediatric AML patients and is associated with adverse outcomes even after allogeneic hematopoietic stem cell transplantation (HSCT). To investigate outcomes and prognostic factors, we investigated 90 pediatric AML patients with KMT2A rearrangement after allogeneic HSCT. We retrospectively analyzed Japanese registration data for patients who had received allogeneic HSCT between 1988 and 2011. Median age was 3 years (range, 0–15 years), and no gender difference was evident. Median observation period was 119 months. The 3-year overall survival (OS) rate of KMT2A -rearranged AML was 52.1% (95% confidence interval (CI), 42.4–64%, n = 90), and the 3-year disease-free survival (DFS) rate was 46.7% (95%CI, 36.8–58.2%). The 3-year DFS of KMT2A -rearranged AML was not significantly poorer than that of other AML (P = 0.09), and no significant difference was also seen in 3-year OS rate (P = 0.21). Multivariate analysis showed disease status (complete remission) at HSCT was associated with better outcomes. A significant difference in treatment-related mortality (TRM) was apparent between HSCT from a HLA full-matched related donor and that from a haploidentical donor (P = 0.001). HSCT is a curative option for pediatric AML with KMT2A rearrangement. Pretransplant status was the most significant prognostic indicator for relapse and survival. Enhancing supportive therapy to reduce TRM will further improve treatment outcomes of KMT2A -rearranged pediatric AML. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.